Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Elderly chronic hepatitis C patients benefit from DAAs

06 Nov 2019

Direct-acting antivirals (DAAs) are effective for chronic hepatitis C even in elderly adults, resulting in respectable rates sustained virological response (SVR) independently of age, a recent study has shown.

Researchers retrospectively examined 1,151 elderly chronic hepatitis C patients who were further disaggregated according to age: 65 years (mean age, 70.85±5.47 years; 59.1 percent male) and <65 years (mean age, 54.06±9.37 years; 62.4 percent male). Comparative DAA efficacy was the primary outcome.

The treatment response rate in the overall cohort was 97.7 percent. This was slightly higher in the younger subgroup (98.3 percent vs 97.1 percent), though the difference was not statistically significant. Twenty-six patients failed treatment; 15 belonged to the older group.

SVR rates 12 weeks after treatment (SVR12) were 97.4 percent, 97.2 percent and 86.7 percent for the 65–74-years, 75–84-years and 85-years age groups, respectively. No between- and among-group differences were reported.

Multivariate logistic regression analysis revealed that the combination of DAAs received (p0.001) and coinfection with HIV (p=0.001) were the only significant predictors of SVR12. Both factors were also initially predictive of treatment response in the older subgroup, though their respective significance were attenuated upon multivariable analysis.

Other variables, such as comorbidities, fibrosis stage, baseline viral load, previous treatment history and demographic factors, were all unrelated to the likelihood of treatment response.

“Treatment should not be withheld purely on the grounds of advanced age, and older age should not be a barrier to [hepatitis C virus] treatment,” said researchers. “Older adults should have the opportunity to benefit from the high cure rates and health benefits associated with viral eradication.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.